RxDoctor Payments Data

Perin Alfred, MD

Pulmonary Disease · Ocala, FLNPI 1285691980

Payments from drug & device makers

$2,909in general payments, 2019–2025

Across 202 payments — averaging $14.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$1K
  • Boehringer Ingelheim$116
  • Electromed, Inc.$108
  • Inogen, Inc.$78
  • United Therapeutics Corporation$71
  • plus $171 from 7 others

What the payments were for

  • Food & beverage$2,87699%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,909 in reported general payments places this provider in the 45th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$207,735
Medicare patients
692
Services billed
1,864

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter546$610,316
OfevNintedanib Esylate18$315,369
Breztri AerosphereBudesonide/Glycopyr/Formoterol207$221,887
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr97$79,067
Stiolto RespimatTiotropium Br/Olodaterol Hcl93$61,715
SymbicortBudesonide/Formoterol Fumarate130$52,858
Breo ElliptaFluticasone/Vilanterol75$43,299
Advair HfaFluticasone Propion/Salmeterol44$24,141
Albuterol Sulfate HfaAlbuterol Sulfate472$14,350
Fluticasone-SalmeterolFluticasone Propion/Salmeterol103$13,242
Bevespi AerosphereGlycopyrrolate/Formoterol Fum13$10,849
Pirfenidone13$8,711
Wixela InhubFluticasone Propion/Salmeterol66$8,321
BreynaBudesonide/Formoterol Fumarate30$7,445
DuleraMometasone/Formoterol16$7,334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,112$732,682718 claims
Boehringer IngelheimOfev, Stiolto Respimat$116$377,084111 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$1,253$285,594350 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →